Table 4.
Summary of Clinical Trials Evaluating Combination Pegylated Interferon Alfa 2A and Ruxolitinib.
| Clinical Trial | Phase | Patients | Comparator Arm | Clinical Response (RR/CR/PR) | Molecular Response (RR/CR/PR) | Discontinuation Rate | |
|---|---|---|---|---|---|---|---|
| RUXOPEG [65] | 1/2 | Intermediate/high-risk MF (n = 15) | None | 0%/NR/NR A | 30%/NR/NR A | NR | NR |
| COMBI [64] | 2 | PV (n = 32) and MF (n = 18) with active disease | None | 31%/9%/22% (PV) B 44%/28%/72% (MF) A |
41%/2%/35% | 6% (PV)32% (MF) | |
A IWG-MRT Clinical response criteria; B ELN response criteria. CR: complete response; MF: myelofibrosis; NR: not reported; PR: partial response; PV: polycythemia vera; pIFN: pegylated interferon; RR: response rate.